Skip to main content
Research CombinationRecoveryEmerging EvidenceEducational · Not medical advice

Thymosin Alpha-1 + LL-37: Immune Support

A broad-spectrum immune support stack combining thymosin alpha-1's T-cell maturation and adaptive immune enhancement with LL-37's antimicrobial peptide activity and innate immune modulation. Thymosin alpha-1 is clinically used to restore immune competence in immunocompromised patients by promoting dendritic cell and NK cell activity, while LL-37 provides direct antimicrobial action and regulates inflammatory signalling. The stack targets both adaptive and innate arms of immunity through complementary mechanisms.

2
Compounds
Emerging
Evidence Level
3
Research Refs
Recovery
Primary Goal

Mechanism

Compound 1Recovery

Thymosin Alpha-1

Restores and amplifies adaptive immune function by promoting T-cell maturation, dendritic cell activity, and NK cell output; clinically validated for immune reconstitution in immunocompromised patients.

+
Compound 2Recovery

LL-37

Provides innate immune reinforcement through direct antimicrobial activity against bacteria, viruses, and fungi while modulating the inflammatory response to prevent immune over-activation.

Synergistic Effect

Dual-pathway activation

Thymosin Alpha-1 × LL-37

Safety Notes

Thymosin Alpha-1 is approved in multiple countries for viral hepatitis and immune deficiencies but is not FDA-approved in the United States. LL-37 is an endogenous antimicrobial peptide; synthetic injectable LL-37 is a research compound with limited human clinical data. Both agents modulate immune function — use in individuals with autoimmune conditions, organ transplants, or on immunosuppressive therapy requires medical supervision. No formal combination safety data exists.

Research References

Established

History of the discovery and clinical development of thymosin alpha1

Expert Opin Biol Ther 2009PMID 19301993
Established

Thymosin alpha 1 reduces the mortality of severe COVID-19 by restoration of lymphocytopenia

Int Immunopharmacol 2020PMID 33162386
Established

Cathelicidins, multifunctional peptides of the innate immunity

J Leukoc Biol 2004PMID 14519849
Browse all →

⚠ Educational Use OnlyPeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Free newsletter

The Peptide Research Digest

Weekly analysis on providers, sourcing and compounds — from the team behind PeptideBase.

No spam. Unsubscribe anytime. Privacy policy.